JP2013544288A5 - - Google Patents

Download PDF

Info

Publication number
JP2013544288A5
JP2013544288A5 JP2013542199A JP2013542199A JP2013544288A5 JP 2013544288 A5 JP2013544288 A5 JP 2013544288A5 JP 2013542199 A JP2013542199 A JP 2013542199A JP 2013542199 A JP2013542199 A JP 2013542199A JP 2013544288 A5 JP2013544288 A5 JP 2013544288A5
Authority
JP
Japan
Prior art keywords
virus
viral
liquid
preparation
viral composition
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Granted
Application number
JP2013542199A
Other languages
English (en)
Japanese (ja)
Other versions
JP6034797B2 (ja
JP2013544288A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2011/063037 external-priority patent/WO2012075376A2/en
Publication of JP2013544288A publication Critical patent/JP2013544288A/ja
Publication of JP2013544288A5 publication Critical patent/JP2013544288A5/ja
Application granted granted Critical
Publication of JP6034797B2 publication Critical patent/JP6034797B2/ja
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

JP2013542199A 2010-12-02 2011-12-02 凍結乾燥されたウイルス製剤 Active JP6034797B2 (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US41902010P 2010-12-02 2010-12-02
US61/419,020 2010-12-02
PCT/US2011/063037 WO2012075376A2 (en) 2010-12-02 2011-12-02 Lyophilized viral formulations

Related Child Applications (1)

Application Number Title Priority Date Filing Date
JP2016170628A Division JP6433954B2 (ja) 2010-12-02 2016-09-01 凍結乾燥されたウイルス製剤

Publications (3)

Publication Number Publication Date
JP2013544288A JP2013544288A (ja) 2013-12-12
JP2013544288A5 true JP2013544288A5 (enExample) 2015-01-22
JP6034797B2 JP6034797B2 (ja) 2016-11-30

Family

ID=46162458

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2013542199A Active JP6034797B2 (ja) 2010-12-02 2011-12-02 凍結乾燥されたウイルス製剤
JP2016170628A Active JP6433954B2 (ja) 2010-12-02 2016-09-01 凍結乾燥されたウイルス製剤
JP2018153546A Withdrawn JP2018172443A (ja) 2010-12-02 2018-08-17 凍結乾燥されたウイルス製剤

Family Applications After (2)

Application Number Title Priority Date Filing Date
JP2016170628A Active JP6433954B2 (ja) 2010-12-02 2016-09-01 凍結乾燥されたウイルス製剤
JP2018153546A Withdrawn JP2018172443A (ja) 2010-12-02 2018-08-17 凍結乾燥されたウイルス製剤

Country Status (15)

Country Link
US (2) US9044498B2 (enExample)
EP (1) EP2646052B1 (enExample)
JP (3) JP6034797B2 (enExample)
KR (1) KR102023207B1 (enExample)
CN (1) CN103269716B (enExample)
AU (1) AU2011336410B2 (enExample)
CA (1) CA2819236A1 (enExample)
DK (1) DK2646052T3 (enExample)
EA (1) EA201390812A1 (enExample)
ES (1) ES2630012T3 (enExample)
IL (1) IL226646B (enExample)
MX (1) MX349294B (enExample)
SG (1) SG190419A1 (enExample)
TW (1) TW201233803A (enExample)
WO (1) WO2012075376A2 (enExample)

Families Citing this family (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SG191602A1 (en) * 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
EP2646051A4 (en) * 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
MX349294B (es) 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2012248082B2 (en) * 2011-04-29 2015-08-20 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
US11273127B2 (en) 2014-05-06 2022-03-15 The Regents Of The University Of Colorado, A Body Corporate Compositions, methods and uses for thermally stable multi-targeted antigens
GB201513010D0 (en) * 2015-07-23 2015-09-09 Glaxosmithkline Biolog Sa Novel formulation
BR112019009113A2 (pt) 2016-11-04 2019-07-16 Baxalta Incorporated formulações de vírus adenoassociado
MY209364A (en) * 2017-10-16 2025-07-03 Serum Institute Of India Pvt Ltd Stable vaccine compositions comprising inter alia live attenuated recombinant flavivirus and process for preparation thereof
KR20210032984A (ko) 2018-07-11 2021-03-25 박스알타 인코퍼레이티드 Aav 조성물
CN110279693B (zh) * 2019-07-25 2021-06-15 军事科学院军事医学研究院微生物流行病研究所 一种组合物在制备预防和/或治疗发热伴血小板减少综合征病毒的药物中的应用
CN112107678B (zh) * 2020-09-30 2022-11-18 辰欣药业股份有限公司 一种含有胸腺法新的冻干组合物及其制备方法
CN116270500B (zh) * 2021-12-30 2025-05-06 安徽贝金基因科技有限公司 一种高稳定性的溶瘤病毒组合物及其制备方法和其应用

Family Cites Families (106)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR2505657A1 (fr) * 1981-05-13 1982-11-19 Pasteur Institut Perfectionnements apportes aux agents de stabilisation de virus vivants pour la preparation de vaccins, et vaccins stabilises contenant lesdits agents de stabilisation
US5023252A (en) 1985-12-04 1991-06-11 Conrex Pharmaceutical Corporation Transdermal and trans-membrane delivery of drugs
US5626851A (en) 1987-11-30 1997-05-06 The Wistar Institute Of Anatomy And Biology Rotavirus reassortant vaccine
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
EP0410207B1 (en) 1989-07-24 1997-01-22 Bayer Corporation Stabilization of highly purified proteins
AU673827B2 (en) 1992-03-24 1996-11-28 United Cancer Research Institute Vaccine containing live virus for therapy of viral diseases and malignancies
CA2075521C (en) * 1992-05-05 1995-11-28 Kuniaki Koyama Stabilized live vaccine
EP0728195A1 (en) 1993-10-12 1996-08-28 Chiron Corporation Methods for preserving recombinant viruses
ATE328068T1 (de) 1994-05-16 2006-06-15 Merck & Co Inc Papillomavirus vakzine
WO1996001651A1 (en) 1994-07-11 1996-01-25 The Government Of The United States Of America, Represented By The Department Of Health And Human Services Attenuated human rotavirus vaccine
US6586006B2 (en) 1994-08-04 2003-07-01 Elan Drug Delivery Limited Solid delivery systems for controlled release of molecules incorporated therein and methods of making same
US6290991B1 (en) 1994-12-02 2001-09-18 Quandrant Holdings Cambridge Limited Solid dose delivery vehicle and methods of making same
US6267958B1 (en) 1995-07-27 2001-07-31 Genentech, Inc. Protein formulation
ES2434840T3 (es) 1995-07-27 2013-12-17 Genentech, Inc. Formulación de proteína liofilizada isotónica estable
US6685940B2 (en) 1995-07-27 2004-02-03 Genentech, Inc. Protein formulation
US6165773A (en) 1995-10-25 2000-12-26 Provalis Uk Limited Methods of preserving viruses
GB9521806D0 (en) 1995-10-25 1996-01-03 Cortecs Ltd Preservation methods
FR2742756B1 (fr) 1995-12-22 1998-04-03 Pasteur Merieux Serums Vacc Stabilisants pour vaccins vivants, vaccins les contenant et procedes pour leur preparation
FR2751343B1 (fr) * 1996-07-16 1998-12-18 Transgene Sa Procede de conservation de virus recombinants infectieux, suspension aqueuse virale et utilisation comme medicament
WO1998013065A1 (en) 1996-09-26 1998-04-02 Merck & Co., Inc. Rotavirus vaccine formulations
US5932223A (en) * 1996-09-26 1999-08-03 Merck & Co., Inc. Rotavirus vaccine formulations
US6403098B1 (en) 1996-09-26 2002-06-11 Merck & Co., Inc. Rotavirus vaccine formulations
US6616931B1 (en) 1996-09-26 2003-09-09 Merck & Co., Inc. Rotavirus vaccine formulations
US7732129B1 (en) 1998-12-01 2010-06-08 Crucell Holland B.V. Method for the production and purification of adenoviral vectors
US20080261289A1 (en) 1996-12-13 2008-10-23 Schering-Plough Corporation Compositions comprising viruses and methods for concentrating virus preparations
US6544769B1 (en) 1996-12-13 2003-04-08 Schering Corporation Compostions comprising viruses and methods for concentrating virus preparations
US6051238A (en) 1996-12-20 2000-04-18 Merck & Co., Inc. Stabilizers for lyophilized mumps vaccines
CA2274755A1 (en) 1996-12-20 1998-07-02 Su-Pi Sheu Stabilizers for lyophilized vaccines
US6290967B1 (en) * 1996-12-20 2001-09-18 Merck & Co., Inc. Stabilizers for lyophilized vaccines
IL137510A0 (en) 1998-02-17 2001-07-24 Schering Corp Compositions comprising viruses and methods for concentrating virus preparations
GB9808922D0 (en) * 1998-04-24 1998-06-24 Cantab Pharmaceuticals Res Ltd Virus preparations
BRPI9912485B8 (pt) 1998-07-28 2021-05-25 The Government Of The Us Secretary Department Of Health And Human Services composição imunogênica multivalente
CN1062770C (zh) * 1998-11-12 2001-03-07 卫生部长春生物制品研究所 甲肝-麻疹二联疫苗及其生产方法
DK1133316T3 (da) 1998-11-16 2009-05-25 Introgen Therapeutics Inc Adenovirus-formulering til genterapi
US6689600B1 (en) 1998-11-16 2004-02-10 Introgen Therapeutics, Inc. Formulation of adenovirus for gene therapy
US6225289B1 (en) 1998-12-10 2001-05-01 Genvec, Inc. Methods and compositions for preserving adenoviral vectors
AU4188100A (en) 1999-04-08 2000-11-14 Gregory M. Glenn Dry formulation for transcutaneous immunization
US6592869B2 (en) 1999-08-24 2003-07-15 Teva Pharmaceutical Industries, Ltd. Vaccine composition and method of using the same
IL148247A0 (en) 1999-08-24 2002-09-12 Teva Pharma A vaccine composition and method of using the same
NZ518401A (en) 1999-10-29 2004-01-30 Nektar Therapeutics Dry powder compositions having improved dispersivity
US7456009B2 (en) * 2000-03-07 2008-11-25 Merck & Co., Inc. Adenovirus formulations
JP5118798B2 (ja) * 2000-03-07 2013-01-16 メルク・シャープ・エンド・ドーム・コーポレイション アデノウイルス製剤
US20020120228A1 (en) 2000-06-08 2002-08-29 Yuh-Fun Maa Powder compositions
JP2003535119A (ja) 2000-06-08 2003-11-25 パウダージェクト ワクチンズ，インコーポレーテッド 粉末組成物
TWI289158B (en) 2000-08-10 2007-11-01 Oncolytics Biotech Inc Method of producing infectious reovirus
GB0020089D0 (en) 2000-08-15 2000-10-04 Smithkline Beecham Biolog Vaccine Composition
JP5063852B2 (ja) 2000-09-25 2012-10-31 ポリマン サイエンティフィック イミューンバイオロジッシュ フォーシュング ゲゼルシャフト ミット ベシュレンクテル ファフツング 生ワクチン及び製造方法
US20040033239A1 (en) 2001-03-06 2004-02-19 Evans Robert K Adenovirus formulations
IL157304A0 (en) 2001-03-16 2004-02-19 Oncolytics Biotech Inc Method of extracting virus from cell culture
WO2002101412A2 (en) 2001-06-08 2002-12-19 Powderject Vaccines, Inc. Spray freeze-dried compositions
GB0124710D0 (en) 2001-10-15 2001-12-05 Quadrant Healthcare Uk Ltd Therapeutic composition
AU2002346424A1 (en) 2001-11-19 2003-06-10 Becton, Dickinson And Company Pharmaceutical compositions in particulate form
CA2469623C (en) 2001-12-12 2012-05-29 F H Faulding & Co Limited Composition for the preservation of viruses
US20030153065A1 (en) 2002-01-14 2003-08-14 Genvec, Inc. Composition and method for maintaining non-enveloped viral vectors
AR038153A1 (es) 2002-01-18 2004-12-29 Schering Ag Formulaciones estabilizadas de adenovirus
US7923029B2 (en) 2002-04-11 2011-04-12 Medimmune Llc Spray freeze dry of compositions for pulmonary administration
WO2003087327A2 (en) 2002-04-11 2003-10-23 Medimmune Vaccines, Inc. Preservation of bioactive materials by freeze dried foam
US20040042972A1 (en) 2002-04-11 2004-03-04 Medimmune Vaccines, Inc. Spray freeze dry of compositions for intranasal administration
DE60327069D1 (de) 2002-04-30 2009-05-20 Oncolytics Biotech Inc Verbesserte reinigungsmethode für viren
CA2503946C (en) 2002-11-01 2016-08-16 Glaxosmithkline Biologicals S.A. Drying process
US6752740B2 (en) 2002-11-12 2004-06-22 Jeffery T. Semmes Continuously variable transmission
CN1745170A (zh) 2002-12-17 2006-03-08 米迪缪尼疫苗股份有限公司 生物活性材料的高压喷雾干燥
US6931888B2 (en) 2003-02-07 2005-08-23 Ferro Corporation Lyophilization method and apparatus for producing particles
ES2529736T3 (es) 2003-04-10 2015-02-25 Novartis Vaccines And Diagnostics, Inc. Composición inmunogénica que comprende una proteína espicular del coronavirus del SARS
WO2005021033A2 (en) * 2003-09-02 2005-03-10 Glaxosmithkline Biologicals S.A. Vaccine
WO2005052116A2 (en) 2003-11-19 2005-06-09 Merck & Co., Inc. Preservative-containing virus formulations
EP1701738B1 (en) 2003-12-17 2015-03-11 Wyeth LLC Method for producing storage stable RSV compositions
WO2005066333A1 (en) 2003-12-30 2005-07-21 Aventis Pasteur, Inc. Stabilizing compositions for recombinant viruses
GB0404586D0 (en) 2004-03-01 2004-04-07 Britannia Pharmaceuticals Ltd Improvements in or relating to organic materials
BRPI0509117A (pt) 2004-03-04 2007-08-28 Wyeth Corp método de liofilização para melhorar a cristalização de excipientes
EP1750760B1 (en) 2004-06-02 2017-06-28 Universal Stabilization Technologies, Inc. Preservation by vaporization
WO2006029467A1 (en) 2004-09-16 2006-03-23 Btf Pty Ltd Rapid freeze drying process
TW200626177A (en) 2004-09-28 2006-08-01 Alza Corp Method and formulation for stabilizing alum-adsorbed vaccines
US7901921B2 (en) 2004-10-22 2011-03-08 Oncolytics Biotech Inc. Viral purification methods
KR101400379B1 (ko) * 2004-11-05 2014-05-28 웰스테트 바이올로직스 코포레이션 안정하고 여과 가능한 외피보유 바이러스 조성물
EP1833385B1 (en) 2004-12-09 2008-08-27 Precimed S.A. Surgical tool holder for facilitated sterilization
US20060141483A1 (en) * 2004-12-23 2006-06-29 Calton Gary J Stabilization of viral compositions
KR20070114753A (ko) 2005-02-18 2007-12-04 아브락시스 바이오사이언스 인크. 치료제의 조합 및 투여 방식, 및 조합 요법
EP1954308B1 (en) * 2005-09-16 2011-09-07 Merial Ltd. Stabilizers for freeze-dried vaccines
CN1765181A (zh) 2005-10-19 2006-05-03 路兴波 高效抗病毒制剂
US7875446B2 (en) 2006-04-20 2011-01-25 Wyeth Llc Purification processes for isolating purified vesicular stomatitis virus from cell culture
US9283260B2 (en) 2006-04-21 2016-03-15 Amgen Inc. Lyophilized therapeutic peptibody formulations
EP1854478A1 (en) 2006-05-12 2007-11-14 Cytos Biotechnology AG Nicotine-carrier vaccine formulation
EP1878791A1 (en) 2006-07-11 2008-01-16 Bia Separations D.O.O. Method for influenza virus purification
DK2055311T3 (en) 2006-08-07 2017-07-24 The Chemo-Sero-Therapeutic Res Inst METHOD OF MANUFACTURING LIVING COPPER VACCINE
US20100129379A1 (en) 2006-09-25 2010-05-27 John Carpenter Stabilized antibody formulations and uses thereof
DK2099485T3 (en) 2006-11-03 2018-05-22 Alphavax Inc Alphavirus and alphavirus replica particle formulations and associated methods
MX2009004862A (es) * 2006-11-07 2009-07-17 Sanofi Pasteur Biologics Co Estabilizacion de vacunas por liofilizacion.
CA2674026C (en) 2006-12-27 2018-08-21 Pfizer Products Inc. Methods of vaccine administration
WO2008106646A2 (en) 2007-03-01 2008-09-04 Introgen Therapeutics, Inc Methods and formulations for topical gene therapy
SG191602A1 (en) * 2007-03-12 2013-07-31 Oncolytics Biotech Inc Reoviruses having modified sequences
GB0705245D0 (en) 2007-03-19 2007-04-25 Stabilitech Ltd Stable biological products
CA2681567C (en) * 2007-03-22 2016-07-19 The Regents Of The University Of Colorado, A Body Corporate Method of preparing an immunologically-active adjuvant-bound dried vaccine composition
WO2009014774A1 (en) 2007-04-06 2009-01-29 Inviragen, Inc. Methods and compositions for live attenuated viruses
TW200909581A (en) 2007-05-21 2009-03-01 Oncolytics Biotech Inc Mutant reoviruses and methods of making and using
WO2009042202A2 (en) 2007-09-25 2009-04-02 Aridis Pharmaceuticals Formulations for preservation of rota virus
JP2011500569A (ja) 2007-10-12 2011-01-06 マサチューセッツ インスティテュート オブ テクノロジー ワクチンナノテクノロジー
WO2009056651A1 (en) 2007-11-02 2009-05-07 Cytos Biotechnology Ag Angiotensin-carrier formulation
JP4932940B2 (ja) 2007-11-12 2012-05-16 セラクローン サイエンシーズ， インコーポレイテッド インフルエンザの治療および診断のための組成物および方法
US8227577B2 (en) 2007-12-21 2012-07-24 Hoffman-La Roche Inc. Bivalent, bispecific antibodies
WO2009108689A1 (en) * 2008-02-25 2009-09-03 Novavax, Inc. Sugar glassified virus like particles (vlps)
LT2805731T (lt) * 2009-09-03 2019-02-11 Ablynx N.V. Stabilios polipeptidų kompozicijos ir jų panaudojimas
EP2646051A4 (en) * 2010-12-02 2014-05-28 Oncolytics Biotech Inc FORMULATIONS OF LIQUID VIRUSES
MX349294B (es) * 2010-12-02 2017-07-21 Oncolytics Biotech Inc Formulaciones virales liofilizadas.
AU2012248082B2 (en) * 2011-04-29 2015-08-20 Oncolytics Biotech Inc. Methods of purifying viruses using gel permeation chromatography
JP6065096B2 (ja) 2015-12-25 2017-01-25 ダイキン工業株式会社 調湿装置

Similar Documents

Publication Publication Date Title
JP2013544288A5 (enExample)
JP2014502275A5 (enExample)
ES2676656T3 (es) Composición estabilizante de almacenamiento en seco para materiales biológicos
CN102727903B (zh) 一种高致病性猪繁殖与呼吸综合征活疫苗jxa1-r株耐热冻干保护剂及制备方法
JP4902103B2 (ja) 凍結乾燥フォームによる生物活性材料の保存
JP5307801B2 (ja) 凍結乾燥フォームによる生物活性材料の防腐
CN102727904B (zh) 一种高致病性猪繁殖与呼吸综合征-伪狂犬病二联活疫苗耐热保护剂及制备方法
CN103041383B (zh) 一种活疫苗的耐热冻干保护剂、活疫苗冻干粉及其制备方法
JP4138314B2 (ja) ロタウイルスワクチン調合物
JP6034797B2 (ja) 凍結乾燥されたウイルス製剤
US20110177119A1 (en) Stable, dried rotavirus vaccine, compositions and process for preparation thereof
JP2012531442A5 (enExample)
CN111655844A (zh) 包含特别是减毒活重组黄病毒的稳定的疫苗组合物及其制备方法
CN103041399A (zh) 一种耐热保护剂及其应用
CN106794145A (zh) 热稳定冻干轮状病毒疫苗制剂及其制备方法
JP2017510585A5 (enExample)
JP2019031543A (ja) 弱毒生アルファウイルス製剤のための組成物および方法
WO2019028976A1 (zh) 耐热保护剂、猪瘟可室温保存活疫苗及其制备方法和应用
CN103893776B (zh) 羊传染性脓疱病毒细胞弱毒疫苗耐热冻干保护剂及其制备方法和应用
CN114767842A (zh) 一种重组卡介苗的冻干制剂及其制备方法和用途
CN103301471A (zh) 一种猪轮状病毒冻干疫苗
HK1236813A1 (en) A thermostable freeze dried rotavirus vaccine formulation and process to prepare thereof
EA046342B1 (ru) Стабильные составы вакцин, включающих, в частности, живой аттенуированный рекомбинантный флавивирус и процесс их приготовления
HK1220358B (en) Compositions and methods for live, attenuated alphavirus formulations